| __timestamp | BioMarin Pharmaceutical Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 1213000 |
| Thursday, January 1, 2015 | 402271000 | 3425000 |
| Friday, January 1, 2016 | 476593000 | 6311000 |
| Sunday, January 1, 2017 | 554336000 | 9518000 |
| Monday, January 1, 2018 | 604353000 | 28080000 |
| Tuesday, January 1, 2019 | 680924000 | 36550000 |
| Wednesday, January 1, 2020 | 737669000 | 46125000 |
| Friday, January 1, 2021 | 759375000 | 68486000 |
| Saturday, January 1, 2022 | 854009000 | 92032000 |
| Sunday, January 1, 2023 | 937300000 | 117532000 |
| Monday, January 1, 2024 | 1009025000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing operational costs is crucial for success. BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, BioMarin has seen a steady increase in SG&A expenses, growing from approximately $302 million in 2014 to $937 million in 2023. This represents a growth of over 200%, reflecting their expansive operational strategies.
Conversely, Rhythm Pharmaceuticals started with a modest $1.2 million in 2014, skyrocketing to $117 million by 2023, marking an exponential increase of nearly 9,600%. This dramatic rise highlights their aggressive market entry and expansion efforts.
Understanding these trends provides valuable insights into how these companies allocate resources to support their growth and market presence.
Merck & Co., Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Sanofi and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Rhythm Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.